Why DMSO Ear Drops Remain an Unproven Tinnitus Treatment

DMSO ear drops are not a proven or FDA-approved treatment for tinnitus, and the available evidence does not establish a safe ear concentration or dosing schedule. The only current registered human pilot combines 50% DMSO with several other active ingredients, enrolls approximately 20 people, and has no placebo group, so it cannot show whether DMSO itself works.

The FDA-approved prescription DMSO product, RIMSO-50, is labeled for bladder instillation for interstitial cystitis—not for the ear. A registered trial does not confer approval or establish effectiveness. The official record for ClinicalTrials.gov study NCT07567274 describes an experimental protocol with no posted efficacy or safety results in the supplied record.

The American Tinnitus Association reports that no pharmaceutical intervention currently eliminates tinnitus and that there are no FDA-approved drugs for treating it. Its medication guidance distinguishes symptom management from a drug cure.

Toggle the trial ingredients to see why its design cannot isolate DMSO or produce a DMSO-only verdict.

This evidence does not support copying the trial schedule, diluting a bladder product, or converting laboratory concentrations into homemade ear drops. No cited human study supplies a validated formulation, amount, frequency, or duration for unsupervised use.

The Evidence Does Not Establish Benefit

Four different sources are commonly presented as though they answer the same question. They do not.

The official RIMSO-50 prescription label identifies it as a sterile 50% aqueous DMSO solution for intravesical instillation—delivery into the bladder—for symptomatic relief of interstitial cystitis. It provides no tinnitus indication or instructions for putting the product into an ear. Approval for this route does not establish safety by another route. See also DMSO’s established and proposed human uses.

A trial registry records a research plan. It is not evidence that participants improved. Even completed results from an uncontrolled trial would be less informative than a randomized, masked comparison because tinnitus fluctuates and its burden is reported subjectively.

Laboratory evidence addresses another question. It may identify cellular effects under controlled conditions, but direct exposure of cultured cochlear tissue is not equivalent to placing formulated liquid in an external ear canal behind an intact eardrum.

The 1975 Report Does Not Supply a Reproducible Treatment

A. Caro reported DMSO-containing treatment in people with tinnitus in 1975 in the Annals of the New York Academy of Sciences. The DOI is 10.1111/j.1749-6632.1975.tb25389.x.

The accessible bibliographic summary of the report describes 15 people with subjective, nonvibratory tinnitus of unknown origin. They received 2 mL of a medicated DMSO spray in the external auditory canal. “Medicated” does not establish that this was DMSO alone, nor does the summary identify the other ingredients.

The clearly stated outcome concerns vertigo, not tinnitus: all five participants who also had vertigo reportedly noted improvement in vertigo. A change in vertigo does not prove a change in tinnitus.

The accessible summary does not report the DMSO concentration, complete formulation, treatment frequency, duration, tinnitus response rate, validated tinnitus measurement, adverse events, statistical analysis or sufficiently detailed follow-up. It also describes no placebo group, random assignment or masking.

A later recruitment page claims that nine of the 15 participants had complete disappearance of tinnitus without recurrence during one year of observation. The accessible historical summary does not provide the tinnitus-specific outcomes and methods needed to substantiate that stronger claim.

The report can support further investigation. It cannot establish efficacy, define ear-specific safety or justify a home protocol decades later.

The Current Pilot Tests Seven Ingredients Through Two Routes

NCT07567274 is an invitation-only Phase 2 pilot for refractory subjective, non-pulsatile tinnitus associated with long COVID or what its protocol calls post-COVID-19 vaccine injury. It was first posted on May 5, 2026, with primary completion listed for July 2026. The supplied registry record contains no completed results.

Estimated enrollment is approximately 20 adults. The intervention lasts 30 days, with longer-term assessments planned. It is a compounded, dual-route combination regimen rather than a trial of DMSO-only ear drops.

The otic solution contains 50% DMSO, betahistine, dexamethasone and lidocaine. The transdermal cream contains DMSO, levocarnitine and N-acetylcysteine. The otic liquid is placed in the external auditory canal every four days, while the cream is applied daily around the ears, mastoid regions and upper posterior neck. Both formulations are described as being prepared by a licensed compounding pharmacy. These protocol details are not instructions for self-treatment.

The primary endpoint is the proportion of participants with at least a 50% reduction from baseline in Tinnitus Handicap Inventory, or THI, score by Day 30. THI measures tinnitus-related burden. A lower THI score could represent a meaningful improvement, but it is not necessarily complete disappearance of the sound, reduced measured loudness or restored hearing.

Eligibility is narrow. Participants must be 18 to 70 years old, have bothersome tinnitus for at least six months, score at least 20 on the screening THI and have failed at least two previous treatments. The tinnitus must fit the study’s specified post-COVID attribution.

The protocol excludes people with pulsatile tinnitus, active middle-ear infection, eardrum perforation or current ear drainage. Pregnancy, breastfeeding and allergy to a formulation ingredient are also exclusions. Results in this selected group would not automatically apply to tinnitus related to noise exposure, aging, hearing loss, medication use, Ménière’s disease or an unidentified cause.

A Single-Arm Pilot Cannot Identify DMSO’s Effect

The study is single-arm and open-label. Every participant receives the active combination, no placebo group is included, and participants and investigators know what treatment is being administered.

This design can explore feasibility and document observations during treatment. It cannot reliably separate treatment effects from placebo effects, expectations, reporting bias, concurrent changes or natural variation.

Regression to the mean is especially relevant. Someone may seek experimental care while tinnitus is unusually severe, after which symptoms can move closer to their usual level regardless of treatment. A control group helps estimate how much change would have occurred without the experimental regimen.

The small estimated sample also limits precision. In approximately 20 participants, a few outcomes can materially alter the response proportion. An invitation-only sample may differ from typical patients in motivation, expectations, medical history or access to care.

Most importantly, all seven ingredients and both delivery routes are used during the same treatment period. If participants improve, the study cannot determine whether the change came from DMSO, another ingredient, an interaction among ingredients, the otic solution, the cream or nonspecific effects. Any favorable result would apply to the complete compounded regimen as studied—not to DMSO-only ear drops.

Stronger evidence would require random allocation, masking where feasible, an appropriate comparator, prespecified outcomes, hearing tests, complete adverse-event reporting and sufficient follow-up. A design intended to answer the DMSO question would also need to separate DMSO from the other active ingredients and distinguish otic treatment from topical treatment.

No Safe Human Ear Concentration Has Been Established

No available human tinnitus evidence establishes a safe DMSO ear-drop concentration, formulation, amount, frequency or treatment duration.

An intact eardrum separates the external auditory canal from the middle ear, and the inner ear lies deeper. External drops therefore do not necessarily expose the cochlea directly. That anatomical distinction does not make an untested product safe, particularly when eardrum status is unknown.

The pilot’s exclusions reinforce this limitation. People with an eardrum perforation, active middle-ear infection or drainage are deliberately excluded. The protocol does not quantify risk in those situations, but it cannot be interpreted as supporting use regardless of ear condition.

A peer-reviewed cochlear-culture study directly exposed cochlear organ cultures from neonatal rats to DMSO for 24 hours. Researchers observed little or no damage at 0.1% and 0.25%. Concentrations from 0.5% through 6% produced dose-dependent stereocilia damage, cellular swelling and hair-cell loss. Injury began in the cochlear base and spread as concentration increased, with inner hair cells showing greater damage than outer hair cells in that model.

Neither finding yields a human dilution formula. Little observed damage at lower laboratory concentrations does not prove safety in a living human ear. Damage at higher concentrations does not define the toxicity threshold for an external ear drop. The experiment immersed neonatal rat cochlear tissue directly in culture medium for a fixed period, which is materially different from external-canal exposure in a person.

Formulation quality presents another unresolved issue. DMSO crosses biological membranes and may increase exposure to accompanying substances. Sterility, purity, excipients, residues, contaminants and combined medicines therefore matter. A topical DMSO product may contain ingredients that have never been evaluated for otic exposure.

The RIMSO-50 bladder label reports occasional hypersensitivity, garlic-like taste or breath or skin odor, possible potentiation of concomitant medicines and monitoring recommendations. Those observations come from intravesical use and cannot establish safety in the external, middle or inner ear. The absence of ear-specific warnings on a bladder label is not evidence that ear use is safe.

Do not put RIMSO-50, industrial DMSO, topical DMSO, commercial mixtures or self-mixed preparations into the ear. Dilution does not convert a bladder or skin product into a validated otic medicine.

Cure Claims Go Beyond the Available Evidence

An alternative-health article titled “How DMSO Cures Eye, Ear, Nose, Throat and Dental Disease” has helped drive interest in DIY DMSO ear treatment. The supplied material provides no tinnitus-specific controlled comparison, validated outcome, complete formulation or ear-specific safety result capable of establishing a cure.

Proposed anti-inflammatory, antimicrobial, neurologic, microcirculatory or membrane-penetration effects may provide reasons to conduct research. They do not show that a compound reaches the relevant human tissue at a useful concentration, improves tinnitus or produces an acceptable balance of benefit and harm.

Testimonials cannot account reliably for natural symptom fluctuation, simultaneous treatment, expectation effects, selective reporting, inaccurate diagnosis or unreported adverse outcomes. Evidence involving DMSO in the bladder, on the skin or in the eye also cannot be transferred automatically to the ear because the exposed tissues and barriers differ.

Evaluation and Burden Reduction Are Better-Supported Options

Tinnitus care starts by checking for an underlying condition or modifiable contributor. Assessment may include a medical history, examination of the ears, head and neck, and a hearing test. Earwax buildup, hearing loss, a causative medicine or a blood-vessel condition may be treatable contributors in some people.

Persistent tinnitus may be managed with hearing aids when hearing loss is present, white-noise or masking devices, tinnitus retraining therapy or cognitive behavioral therapy. Associated insomnia, anxiety or depression can also be treated. These approaches aim to reduce distress and interference rather than promise that the sound will disappear.

Mayo Clinic’s tinnitus diagnosis and treatment guidance describes evaluation for possible causes and established burden-reduction options. Clinical assessment is particularly appropriate for new, one-sided or pulsatile tinnitus, or tinnitus accompanied by hearing change, drainage or significant vertigo.

The practical decision is not to improvise a DMSO regimen. Seek evaluation for possible contributors, use established approaches to reduce tinnitus burden where appropriate, and monitor NCT07567274 for complete results and peer-reviewed analysis.